ProfileGDS5678 / 1453928_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 96% 96% 96% 96% 95% 95% 94% 96% 96% 96% 96% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.4491695
GSM967853U87-EV human glioblastoma xenograft - Control 28.7038796
GSM967854U87-EV human glioblastoma xenograft - Control 38.9259696
GSM967855U87-EV human glioblastoma xenograft - Control 49.0151396
GSM967856U87-EV human glioblastoma xenograft - Control 58.7941596
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.3628195
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.1418895
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.2394694
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.6926496
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.7340996
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.6995896
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.7710196
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.9145996
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.8291896